Responsibility is one incentive when retail investors seek investments. Pharmaceuticals and healthcare is one of the most interesting sectors.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.
Orion published Financial Statement Release for 2019 on Wednesday, 5 February 2020. The release, presentation material and link to live webcast recording are available here.
Orion Investor Relations have received several questions related to the coronavirus (COVID-19) pandemia and its impacts on Orion. We have listed here answers to some frequently asked questions.
Information and instructions for shareholders who have shares on joint account.
Impact of Darolutamide on Pain and Quality of Life in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) at ASCO taking place in Chicago.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
|3/19/2020||Orion cancels its Annual General Meeting on Wednesday 25 March 2020 and postpones it to a later date|
|3/5/2020||Orion Corporation: Change in Orion Group Executive Management Board as of 1 April 2020|
|3/2/2020||Orion Corporation: Transfer of 94,317 own B shares on 2 March 2020|
|3/2/2020||Orion Group Financial Statement documents 2019 and Corporate Governance Statement published|
|3/30/2020||Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer|
|2/13/2020||Tero Närvänen is appointed Orion's new Vice President Quality Management as of 1 May 2020|
|1/31/2020||Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer|
|1/30/2020||Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Orion Corporation has been included in the globally recognised FTSE4Good Index.